Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.

7.29 0.11 −1.49%
Market cap
$456.8M
P/E
0.0×
Fwd P/E
−5.1×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— — 4 4
ROE
(88.89%) (74.65%) (55.26%) (44.87%)
ROA
(68.44%) (56.67%) (44.31%) (37.69%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(82.56%) (54.17%) (50.90%) (38.88%)
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.47) (1.56) (1.34) (1.33)
Free Cash Flow
(76.84) (81.70) (78.86) (81.37)
Other line items

Show all line items

Columns are period end dates